The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samples

DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search for more than 11,000 different microbes and parasites. The mNGS analysis can be done directly from cell-free DNA samples from blood, in less than 24 hours after sample receipt. This advanced mNGS clinical research approach can be valuable for bloodstream infections, sepsis, endocarditis, and other severe infectious diseases.

Following the acquisition, DISQVER® remains available for research use only, while Bruker is progressing its registration for diagnostic purposes. Financial details of the transaction were not disclosed, and DISQVER® is not expected to be material to Bruker’s FY26 financial results.